Market Overview

Robbins Arroyo LLP: Lannett Company (LCI) Misled Shareholders According to a Recently Filed Class Action


Shareholder rights law firm Robbins
Arroyo LLP
announces that purchasers of Lannett Company (NYSE:LCI)
have filed a class action complaint against the company's officers and
directors for alleged violations of the Securities Exchange Act of 1934
between February 7, 2018 and August 17, 2018. Lannett develops,
manufactures, packages, markets, and distributes generic versions of
brand pharmaceutical products in the United States.

View this information on the law firm's Shareholder Rights Blog:

Lannett Accused of Misleading Investors About Its Risk of Losing
Major Exclusivity Agreement

According to the complaint, Lannett has an exclusivity agreement with
its primary supplier, Jerome Stevens Pharmaceuticals ("JSP"), which is
set to expire on March 23, 2019. JSP's products have historically
accounted for at least one-third of Lannett's sales. Lannett represented
to investors that the company was focused on strengthening its
relationship with JSP. It therefore came as a surprise to investors
when, on August 20, 2018, Lannett announced that its distribution
agreement with JSP would not be renewed. On this news, Lannett's stock
plummeted over 60% to close at $5.35 per share that day, and has yet to

Lannett Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!